Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
June 18, 2018
Fact of the Week: If Drug Price Controls Were Lifted Throughout the OECD, the Number of new Treatments Available Would Increase 9 to 12 Percent by 2030
If drug price controls were lifted throughout the OECD, the number of new treatments available would increase 8 to 13 new drug compounds by 2030, writes John Wu in Innovation Files.
May 9, 2018
Please join ITIF for an event discussing needed policies to ensure sustained U.S. life-sciences leadership.
May 7, 2018
Any effective U.S. life-sciences innovation policy needs to level the global playing field by taking more forceful action to address unfair trade practices, Joe Kennedy writes for Stat News.
April 30, 2018
Intellectual property rights go a long way to helping transform clever ideas into life-saving products that address global health challenges, ITIF’s Stephen Ezell and Mark Schultz of the Southern Illinois University School of Law write for Brink News.
April 24, 2018
Twenty-five case studies underscore how innovators in developing countries—often enabled by robust IP rights—are achieving advances in life sciences and healthcare that benefit people around the world.
April 24, 2018
Please join ITIF and the Center for the Protection of Intellectual Property for an event releasing a new report that documents 25 cases of primarily developing-world entrepreneurs meeting global health challenges by “innovating for health.” The event will discuss what policies, including intellectual property, are needed to underpin successful life-sciences innovation in both the developed and developing world and feature presentations from several developing-country healthcare innovators who are leveraging IP, science, and technology to create a better world.
March 26, 2018
America’s lead in life sciences is being challenged. Other countries are aggressively seeking to attract and grow companies with innovation-based tax incentives, a range of firm-specific enticements, increased government research funding, improved IP protections, and streamlined regulatory approval processes. The federal government should act to ensure U.S. life sciences remain competitive.
February 12, 2018
Life-sciences companies grow best in locations that can combine qualities like a good business environment, skilled workers, strong research universities, and available capital. Strengthening these and related factors can give states a stronger competitive advantage.
December 4, 2017
Innovation Fact of the Week: NIH Would Need an Additional $11.6 Billion to Bring its Funding Back to Where it was in 2003 as a Share of GDP
For the U.S. government to restore National Institutes of Health funding to a level comparable to 2003, it would have had to allocate an additional $11.6 billion dollars last year, writes John Wu in Innovation Files.
November 28, 2017
The number of technology-based start-ups surged 47 percent in the last decade. These firms still account for a relatively small share of all businesses, but they have an outsized impact on economic growth, because they provide better-paying, longer-lasting jobs than other start-ups, and they contribute more to innovation, productivity, and competitiveness.